211689-30-4

Upstream product

• 211689-77-9 2-(2-{2-[2-tert-butoxycarbonylamino-3-(1H-indol-3-yl)-propionylamino]-3-phenyl-propionylamino}-3-phenyl-propylcarbamoyl)-succinic acid 4-tert-butyl ester 1-(4-nitro-benzyl) ester 
• 211689-63-3 (2-{2-[2-tert-butoxycarbonylamino-3-(1H-indol-3-yl)-propionylamino]-3-phenyl-propionylamino}-3-phenyl-propyl)-carbamic acid benzyl ester 
• 211689-76-8 [1-[1-(1-aminomethyl-2-phenyl-ethylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(1H-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester 
• 211689-79-1 2-(4-Nitrobenzyloxycarbonyl)succinic acid 4-tert-butyl ester 
• 211689-78-0 2-((R)-2-{(S)-2-[(S)-2-Amino-3-(1H-indol-3-yl)-propionylamino]-3-phenyl-propionylamino}-3-phenyl-propylcarbamoyl)-succinic acid 1-(4-nitro-benzyl) ester 

Relevant academic research and scientific papers

Insertion of 2-carboxysuccinate and tricarballylic acid fragments into cyclic-pseudopeptides: New antagonists for the human tachykinin NK-2 receptor

A series of cylic pseudopeptides were the synthesized containing the sequence -Trp-Phe-(D)PheΨCH2NH-, the terminal ends of which were bound to 2-carboxy succinate or enantiomerically enriched tricarballylic acid to give the final cyclic structu